Clinical Trial: MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial

U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07381699) titled 'MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial' on Jan. 24.

Brief Summary: This study was designed to compare the efficacy and safety of MRG003 combined with Pucotenlimab as first-line treatment for recurrent or metastatic nasopharyngeal cancer.

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condition: Recurrent/Metastatic Nasopharyngeal Carcinoma

Intervention: DRUG: MRG003 and Pucotenlimab

MRG003 combined with Pucotenlimab, administered on Day 1 every 3 weeks (D1 Q3W), until disease progression (PD), unacceptable toxicity, or death.

Recruitment Status: NOT...